Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. (2018). Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(4), 209-217. doi: 10.21608/aeji.2018.23078
Mohamed Fathallah; Mohammed Elhamouly; Amany Moustafa; Ahmed Gaber. "Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients". Afro-Egyptian Journal of Infectious and Endemic Diseases, 8, 4, 2018, 209-217. doi: 10.21608/aeji.2018.23078
Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. (2018). 'Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients', Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(4), pp. 209-217. doi: 10.21608/aeji.2018.23078
Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018; 8(4): 209-217. doi: 10.21608/aeji.2018.23078
Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients
1Department of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background and study aim: Recently, multiple regimens of different direct-acting antiviral agents (DAAs) have been emerged. We aimed to assess the efficacy, safety and improvement of liver profile for patients treated with regimens of direct acting-antivirals in Egypt. Patients and Methods: A retrospective observational study was conducted at Suez governorate, including a simple random sample of 76 patients treated with directly-acting antiviral therapy and came to our center to enroll our follow up program after antiviral therapy from November 2015 to May 2016. Sustained viral response (SVR) was established at week 12 after end of treatment. Results: A total of 76 chronic hepatitis C patients initiated treatment with DAAs. Forty patients (52.6%) were treated with triple therapy and thirty-six patients (47.3%) with dual therapy. All patients were treated for 12 weeks. According to Intention to treat analysis, 35 of 40 patients (87%) who treated with triple therapy achieved SVR while 32 of 36 patients (88.9%) treated with dual therapy achieved SVR. However, the difference between responders after both regimens wasn’t statistically significant (p= 1). In the group treated with triple therapy, significantly more patients had anemia, leukopenia and thrombocytopenia with no serious side effects leading to discontinuation of therapy. Conclusion: Both regimens had similar efficacy, but the dual therapy was more tolerated with less side effect profile.
Top